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The definition of 'advanced' hepatocellular carcinoma (HCC) has been vague and included various stages. This term has sometimes meant 'multinodular/unresectable HCC', 'HCC with vascular invasion', or 'HCC with extra-hepatic spread'. Since the introduction of the Barcelona Clinic Liver Cancer (BCLC) stage in 1999, the term 'advanced HCC' has been defined as a symptomatic tumor and/or invasive tumoral pattern (vascular invasion/ extrahepatic spread). 1 Based on data suggesting limited efficacy of cytotoxic systemic chemotherapy and results from the SHARP trial, 2,3 sorafenib, a multi-kinase inhibitor, is now the only drug which has been shown to prolong the survival of patients with HCC with vascular invasion or metastasis.
Transarterial chemoembolization (TACE) is the standard of care for patients with multinodular HCC. 4 Although there is not a standardized procedure with different embolic or chemotherapeutic agents, different arterial selectivity before embolization, or different schedules and indications for repeated sessions, 5 TACE has been shown to be effective in prolonging survival compared to supportive care in randomized controlled trials and meta-analyses. 5, 6 However, the outcomes of TACE depend upon patient selection. In a randomized trial which recruited HCC patients with compensatory cirrhosis, good performance status, and large or multinodular HCC with neither portal vein invasion nor distant metastasis, the 2-year survival rate was 63% compared to 27% for the untreated control group (P=0.009). 7 In another randomized trial, inclusion of patients with symptoms or limited portal vein invasion resulted in a 2-year survival rate of 31%. 6 In a subgroup analysis, TACE offered no survival benefit in patients with portal vein invasion. In addition to high rates of tumor recurrence or progression after the procedure, TACE promotes vascular endothelial growth factor (VEGF) production and subsequent angiogenesis. Therefore, apart from adverse events, In a Japanese study, low doses of 5-FU (170 mg/m 2 on day [1] [2] [3] [4] [5] and low doses of cisplatin (7 mg/m 2 on day 1-5) were infused through a subcutaneously-implanted port in HCC patients with portal vein thrombosis. 8 An important point of this study is that the effect of TACE monotherapy is a sub-optimal therapy for HCC with a substantial tumor burden, and so TACE is not beneficial in extensive (or diffusely involved) cases of HCC with or without portal vein invasion. For therapies for advanced HCC, we are armed with more treatment modalities than before. Besides HAIC, the efficacy of multimodal approaches with external beam radiation therapy, internal radiation with Yttrium-90, and combination therapies using sorafenib and other treatments for advanced HCC need to be validated by well-designed studies. 13, 14 
